CytRx's (CYTR) INNO-2006 Granted Ophan Drug Status by FDA
Tweet
Share
E-mailGet Alerts CYTR Hot Sheet
Join SI Premium – FREE
CytRx Corporation (Nasdaq: CYTR) said the FDA has granted INNO-206 orphan drug designation for the treatment of patients with soft tissue sarcomas.
Soft tissue sarcomas are cancers that are formed in the muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body. CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.
Soft tissue sarcomas are cancers that are formed in the muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body. CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Hyperfine wins FDA clearance for updated portable MRI software
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
